Results 61 to 70 of about 743,694 (262)

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

A case of synchronous bilateral breast cancer with different pathological responses to neoadjuvant chemotherapy with different biological character [PDF]

, 2013
We report a case of synchronous locally advanced bilateral breast cancer with different pathological responses to neoadjuvant chemotherapy with different biological character.
Hirotaka Iwase, Mitsuhiro Hayashi, Noboru Takata, Yutaka Yamamoto   +3 more
core   +1 more source

Detection of circulating tumor DNA in colorectal cancer patients using a methylation‐specific droplet digital PCR multiplex

Molecular Oncology, EarlyView.
We developed a cost‐effective methylation‐specific droplet digital PCR multiplex assay containing tissue‐conserved and tumor‐specific methylation markers. The assay can detect circulating tumor DNA with high accuracy in patients with localized and metastatic colorectal cancer.
Luisa Matos do Canto, Louise Raunkilde, Jan Lindebjerg, Mads Malik Aagaard, Christina Therkildsen, Jakob Kleif, Lars Henrik Jensen, Torben Frøstrup Hansen, Rikke Fredslund Andersen   +8 more
wiley   +1 more source

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer [PDF]

, 2015
Neoadjuvant chemotherapy plus trastuzumab (NCT) increases the rate of pathological complete response (pCR) and event-free survival (EFS) compared to neoadjuvant chemotherapy (NC) alone in women with HER2 positive breast cancer (BC).
Ades, F, Ahmed, R, Asher, R, Beresford, M, De Azambuja, E, Gojis, O, Howell, SJ, Januszewski, A, Lewanski, C, Lythgoe, D, Macpherson, IRJ, Owadally, W, Palmieri, C, Riddle, P, Shah, D, Stanley, B, Yan, K   +16 more
core   +2 more sources

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

Molecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal   +16 more
wiley   +1 more source

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
A Goldhirsch, A Hurtado, A Noske, AA Lazar, AC Wolff, Andre Robidoux, BM Müller, Bruno V Sinn, C Denkert, Carsten Denkert, Christine Solbach, CK Osborne, D Slamon, DG Altman, DJ Dabbs, EA Perez, EH Romond, FL Baehner, G Hennig, G Konecny, G Pentheroudakis, G von Minckwitz, G von Minckwitz, G von Minckwitz, Gunter von Minckwitz, H Joensuu, Hans Tesch, I Pinhel, J Baselga, J Baselga, Jan C Brase, Jens Huober, Judith Prinzler, K Bohmann, Keyur Mehta, Knut Engels, L Gianni, L Gianni, LM McShane, M Bonetti, M Dowsett, M Dowsett, M Filipits, M Untch, M Untch, M Untch, M Untch, Martin-Leo Hansmann, Mattea Reinisch, ME Hammond, Michael Untch, MJ Piccart-Gebhart, MP Fereshteh, PC Roche, Peter A Fasching, Ralf Kronenwett, S Johnston, S Paik, S Paik, Sibylle Loibl, Silvia Darb-Esfahani, T Lahusen, W Zhao   +62 more
core   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis

Breast Cancer Research
Background Currently, the primary methods for detecting HER2 expression levels are immunohistochemistry (IHC) and in situ hybridization (ISH), with the traditional standard being a HER2-positive score of 3 + accompanied by ERBB2 gene amplification ...
Francisco Cezar Aquino de Moraes, Caio Henrique Duarte de Castro Ribeiro, Felipe Dircêu Dantas Leite Pessôa, Juliana Ramos Chaves, Ana Paula Borges de Souza, Diego Di Felipe Ávila Alcantara, Margareth Maria Braun Guimarães Imbiriba, Maria Cristina Figueroa Magalhães, Rommel Mario Rodríguez Burbano   +8 more
doaj   +1 more source

Pathological Response Patterns to Preoperative Chemoradiation and the Factors Determining Pathological Complete Response in Locally Advanced Carcinoma Rectum

Indian Journal of Colo-Rectal Surgery
Background: Rectal cancer is a formidable health problem worldwide. It is the third most common cancer in men (663,000 cases, 10.0% of all cancer cases) and the second most common in women (571,000 cases, 9.4% of all cancer cases). Rectal cancer accounts
S. Subbiah Shanmugam, Aravind Shivakumar
doaj   +1 more source

Clinician emotional response toward narcissistic patients. A preliminary report [PDF]

, 2015
Patients with narcissistic personality disorder (NPD) are among the most difficult to treat in therapy, especially for their strong resistance to treatment and several difficulties in establishing a therapeutic relationship characterized by intimacy ...
Colli, Antonello, Lingiardi, Vittorio, Muzi, Laura, Tanzilli, Annalisa   +3 more
core   +2 more sources